Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acoramidis - BridgeBio Pharma

Next Previous
Drug Profile

Acoramidis - BridgeBio Pharma

Alternative Names: Acoramidis hydrochloride; AG-10; AG10 hydrochloride; ALXN 2060; Attruby; BBP-265; BEYONTTRA; Beyonttra

Latest Information Update: 17 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Alexion AstraZeneca Rare Disease; Bayer; BridgeBio Pharma; Eidos Therapeutics
  • Class Benzoic acids; Ethers; Fluorobenzenes; Pyrazoles; Small molecules
  • Mechanism of Action Prealbumin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 11 Jun 2026 DKSH enters into a strategic distribution and commercialization agreement with BridgeBio for Acoramidis for the treatment of wild-type and variant transthyretin-mediated amyloid cardiomyopathy in Australia, Singapore, South Korea, and Taiwan
  • 06 May 2026 Registered for Transthyretin-related hereditary amyloidosis in Brazil (PO)
  • 06 May 2026 Bayer plans to launch Acoramidis for Transthyretin-related hereditary amyloidosis in Brazil the second half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top